Bamlanivimab 700mg/20ml solution for infusion vials
Prescription only
Requires a prescription from a doctor or prescriber
Active ingredients:
Bamlanivimab
No active safety alerts
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Source: MHRA Products DatabaseOGL 3.0
Updated 3 months ago(16 Jan 2026)Safety monitoring data
Yellow Card reports
MHRA
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
EMA
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Show details
Clinical guidelines and formulary information
British National Formulary
Bamlanivimab
BNF
Drug monograph — bnf.nice.org.ukSource: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Show details
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
Show details
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA).
Active and completed clinical studies from ClinicalTrials.gov
Show details
Searching UK clinical trials...
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Bamlanivimab is a neutralizing recombinant human IgG1κ monoclonal antibody direc…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Metabolism
As a monoclonal antibody, it is expected that bamlanivimab will be degraded by proteases in various locations throughout the body.…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Status:
Approved
Biologic
About this compound
Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19.[A224039][L15311][L15316] Bamlanivimab is a neutralizing IgG1κ mAb directed against the SARS-CoV-2 spike (S) protein, which is described to block viral entry into human cells.[A224039][L15311][L15316][L20979]
AbCellera initially discovered bamlanivimab in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), and subsequently further developed it in collaboration with Eli Lilly and Company. Bamlanivimab consists of two identical light chains of 214 amino acids and two identical heavy chains of 455 amino acids each; the Fc region is unmodified.[L20979] Bamlanivimab is produced in Chinese Hamster Ovary (CHO) cells.[L20979] Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020.[A224044][L20974] It is set to enter phase 3 clinical trials.[L15316][L15321]
Under the EUA granted in February 2021, bamlanivimab is used in combination with [etesevimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns.[L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children.[L40179]
AbCellera initially discovered bamlanivimab in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), and subsequently further developed it in collaboration with Eli Lilly and Company. Bamlanivimab consists of two identical light chains of 214 amino acids and two identical heavy chains of 455 amino acids each; the Fc region is unmodified.[L20979] Bamlanivimab is produced in Chinese Hamster Ovary (CHO) cells.[L20979] Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020.[A224044][L20974] It is set to enter phase 3 clinical trials.[L15316][L15321]
Under the EUA granted in February 2021, bamlanivimab is used in combination with [etesevimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns.[L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children.[L40179]
Properties:
liquid
DrugBank indication
Bamlanivimab is not currently approved for any indication by the FDA.
[L20974]
Bamlanivimab is authorized under an Emergency Use Authorization (EUA) for the treatment of mild to moderate COVID-19 in patients aged 12 years and older weighing at least 40 kg who are at high risk for progressing to severe COVID-19 and/or hospitalization due to COVID-19. Patients should have confirmed COVID-19, with identification of SARS-CoV-2 viral load by an approved test.
[L20974][L20979]
Under this EUA, bamlanivimab is not authorized in patients who are hospitalized due to COVID-19, who require oxygen due to COVID-19, or in patients on oxygen therapy for non-COVID-19-related comorbidity who require an increased oxygen flow rate due to COVID-19.
[L20974][L20979]
Bamlanivimab in combination with etesevimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. This combination regimen is also used for post-exposure prophylaxis of COVID-19 in unvaccinated or immunocompromised adults and pediatric individuals, including neonates, who are at high risk of progression to severe COVID-19, including hospitalization or death.
[L40184]
[L20974]
Bamlanivimab is authorized under an Emergency Use Authorization (EUA) for the treatment of mild to moderate COVID-19 in patients aged 12 years and older weighing at least 40 kg who are at high risk for progressing to severe COVID-19 and/or hospitalization due to COVID-19. Patients should have confirmed COVID-19, with identification of SARS-CoV-2 viral load by an approved test.
[L20974][L20979]
Under this EUA, bamlanivimab is not authorized in patients who are hospitalized due to COVID-19, who require oxygen due to COVID-19, or in patients on oxygen therapy for non-COVID-19-related comorbidity who require an increased oxygen flow rate due to COVID-19.
[L20974][L20979]
Bamlanivimab in combination with etesevimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. This combination regimen is also used for post-exposure prophylaxis of COVID-19 in unvaccinated or immunocompromised adults and pediatric individuals, including neonates, who are at high risk of progression to severe COVID-19, including hospitalization or death.
[L40184]
Also known as(4)
Bamlanivimab
E2
Peplomer protein
S glycoprotein
Dosage forms(2)
Injection, solution (Intravenous) — 35 mg/1mL
Solution (Intravenous) — 700 mg / 20 mL
Drug interactions(393)
Known interactions with other medications. Always consult a healthcare professional.
Diethylstilbestrol
Moderate
Diethylstilbestrol may increase the thrombogenic activities of Bamlanivimab.
Chlorotrianisene
Moderate
Chlorotrianisene may increase the thrombogenic activities of Bamlanivimab.
Conjugated estrogens
Moderate
Conjugated estrogens may increase the thrombogenic activities of Bamlanivimab.
Estrone may increase the thrombogenic activities of Bamlanivimab.
Estradiol may increase the thrombogenic activities of Bamlanivimab.
Dienestrol
Moderate
Dienestrol may increase the thrombogenic activities of Bamlanivimab.
Ethinylestradiol
Moderate
Ethinylestradiol may increase the thrombogenic activities of Bamlanivimab.
Mestranol may increase the thrombogenic activities of Bamlanivimab.
Estriol may increase the thrombogenic activities of Bamlanivimab.
Estrone sulfate
Moderate
Estrone sulfate may increase the thrombogenic activities of Bamlanivimab.
Quinestrol
Moderate
Quinestrol may increase the thrombogenic activities of Bamlanivimab.
Hexestrol may increase the thrombogenic activities of Bamlanivimab.
Tibolone may increase the thrombogenic activities of Bamlanivimab.
Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Bamlanivimab.
Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bamlanivimab.
Polyestradiol phosphate
Moderate
Polyestradiol phosphate may increase the thrombogenic activities of Bamlanivimab.
Esterified estrogens
Moderate
Esterified estrogens may increase the thrombogenic activities of Bamlanivimab.
Zeranol may increase the thrombogenic activities of Bamlanivimab.
Equol may increase the thrombogenic activities of Bamlanivimab.
Promestriene
Moderate
Promestriene may increase the thrombogenic activities of Bamlanivimab.
Methallenestril
Moderate
Methallenestril may increase the thrombogenic activities of Bamlanivimab.
Epimestrol
Moderate
Epimestrol may increase the thrombogenic activities of Bamlanivimab.
Moxestrol may increase the thrombogenic activities of Bamlanivimab.
Estradiol acetate
Moderate
Estradiol acetate may increase the thrombogenic activities of Bamlanivimab.
Estradiol benzoate
Moderate
Estradiol benzoate may increase the thrombogenic activities of Bamlanivimab.
Estradiol cypionate
Moderate
Estradiol cypionate may increase the thrombogenic activities of Bamlanivimab.
Estradiol valerate
Moderate
Estradiol valerate may increase the thrombogenic activities of Bamlanivimab.
Biochanin A
Moderate
Biochanin A may increase the thrombogenic activities of Bamlanivimab.
Formononetin
Moderate
Formononetin may increase the thrombogenic activities of Bamlanivimab.
Estetrol may increase the thrombogenic activities of Bamlanivimab.
The risk or severity of adverse effects can be increased when Cetuximab is combined with Bamlanivimab.
Human immunoglobulin G
Unknown severity
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bamlanivimab.
Omalizumab
Unknown severity
The risk or severity of adverse effects can be increased when Omalizumab is combined with Bamlanivimab.
Adalimumab
Unknown severity
The risk or severity of adverse effects can be increased when Adalimumab is combined with Bamlanivimab.
The risk or severity of adverse effects can be increased when Abciximab is combined with Bamlanivimab.
Gemtuzumab ozogamicin
Unknown severity
The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bamlanivimab.
Indium In-111 satumomab pendetide
Unknown severity
The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bamlanivimab.
Infliximab
Unknown severity
The risk or severity of adverse effects can be increased when Infliximab is combined with Bamlanivimab.
Trastuzumab
Unknown severity
The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bamlanivimab.
The risk or severity of adverse effects can be increased when Rituximab is combined with Bamlanivimab.
Basiliximab
Unknown severity
The risk or severity of adverse effects can be increased when Basiliximab is combined with Bamlanivimab.
The risk or severity of adverse effects can be increased when Muromonab is combined with Bamlanivimab.
Digoxin Immune Fab (Ovine)
Unknown severity
The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bamlanivimab.
Ibritumomab tiuxetan
Unknown severity
The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bamlanivimab.
Tositumomab
Unknown severity
The risk or severity of adverse effects can be increased when Tositumomab is combined with Bamlanivimab.
Alemtuzumab
Unknown severity
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bamlanivimab.
Capromab pendetide
Unknown severity
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bamlanivimab.
Efalizumab
Unknown severity
The risk or severity of adverse effects can be increased when Efalizumab is combined with Bamlanivimab.
Antithymocyte immunoglobulin (rabbit)
Unknown severity
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bamlanivimab.
Natalizumab
Unknown severity
The risk or severity of adverse effects can be increased when Natalizumab is combined with Bamlanivimab.
Showing 50 of 393 interactions
Toxicity & overdose
Bamlanivimab has been administered at doses of 7000 mg (ten times the authorized dose) during phase 2 clinical trials without any observed dose-limiting toxicity. In the event of an overdose, the recommended treatment is symptomatic and supportive measures; there is no antidote for bamlanivimab overdose.
[L20979]
[L20979]
How it works
Mechanism of action
Bamlanivimab is a neutralizing recombinant human IgG1κ monoclonal antibody directed against the spike (S) surface protein of SARS-CoV-2 derived from screening antigen-specific B-cells from a convalescent COVID-19 patient.[A224039][L20979] X-ray crystallography and cryo-EM structural determination suggest that bamlanivimab binds the receptor-binding domain (RBD) of the S protein at a position overlapping the ACE2 binding site and which is accessible in both the up and down conformations of the RBD.[A224039] Specifically, bamlanivimab binds to the S protein with a KD of 0.071 nM and blocks S protein-ACE2 interactions with an IC50 value of 0.025 μg/mL.[L20979]
Pharmacodynamics
Bamlanivimab is a recombinant human IgG1κ monoclonal antibody directed against the spike (S) surface protein of SARS-CoV-2. Patients in a phase 2 trial were administered up to 7000 mg (ten times the authorized dose) with no increase in treatment-related adverse effects and a flat exposure-response relationship over ranges of 700-7000 mg. Despite generally mild adverse effects noted in the phase 2 trial, there is a risk of serious infusion-related hypersensitivity reactions with bamlanivimab, including anaphylaxis, which may necessitate slowing the infusion rate or discontinuing treatment entirely.[L20979]
Pharmacokinetics
How the body processes this drug — absorption, distribution, metabolism, and elimination
Metabolism
As a monoclonal antibody, it is expected that bamlanivimab will be degraded by proteases in various locations throughout the body. Bamlanivimab is not metabolized by cytochrome P450 enzymes, making drug interactions unlikely.
[L20979]
[L20979]
Scientific references(2)
Jones B.E., Brown-Augsburger P.L., Corbett K.S., Westendorf K., Davies J., Cujec T.P., Wiethoff C.M., Blackbourne J.L., Heinz B.A., Foster D., Higgs R.E., Balasubramaniam D., Wang L., Bidshahri R., Kraft L., Hwang Y., Zentelis S., Jepson K.R., Goya R., Smith M.A., Collins D.W., Hinshaw S.J., Tycho S.A., Pellacani D., Xiang P., Muthuraman K., Sobhanifar S., Piper M.H., Triana F.J., Hendle J., Pustilnik A., Adams A.C., Berens S.J., Baric R.S., Martinez D.R., Cross R.W., Geisbert T.W., Borisevich V., Abiona O., Belli H.M., de Vries M., Mohamed A., Dittmann M., Samanovic M., Mulligan M.J., Goldsmith J.A., Hsieh C.L., Johnson N.V., Wrapp D., McLellan J.S., Barnhart B.C., Graham B.S., Mascola J.R., Hansen C.L., Falconer E.
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv. 2020 Oct 1. doi: 10.1101/2020.09.
30
318972
Chen P., Nirula A., Heller B., Gottlieb R.L., Boscia J., Morris J., Huhn G., Cardona J., Mocherla B., Stosor V., Shawa I., Adams A.C., Van Naarden J., Custer K.L., Shen L., Durante M., Oakley G., Schade A.E., Sabo J., Patel D.R., Klekotka P., Skovronsky D.M.
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med. 2020 Oct 28.
doi: 10
1056/NEJMoa2029849
Affected organisms(1)
SARS-CoV-2
Experimental properties(2)
Commercial products(2)
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Bamlanivimab
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
Show earlier publications
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
Source: go.drugbank.comCC BY-NC 4.0
Updated 30 days ago(4 Mar 2026)